Lifestores and the Limits of Owning the Pharmacy You Sell Software To

Most companies trying to sell software to independent pharmacies start with the software. Lifestores Healthcare started by running pharmacies. Founded in 2017 by Bryan Mezue and Andrew Garza, according to public funding records, the company built a retail chain and a chronic-disease support programme before it built OGApharmacy, the B2B marketplace that now sells procurement, credit and software to other pharmacies. That ordering is the interesting part of the story, and it is also the part that creates the tension worth examining.

Two businesses wearing one name

Lifestores Pharmacy's consumer site describes a retail chain that buys directly from manufacturers and importers, runs everyday-low-price positioning, and supports chronic-disease management, with hypertension named specifically. Lifestores Healthcare's B2B site describes something else: a marketplace, OGApharmacy, aimed at independent pharmacies, promising to cut procurement costs by 10 to 20 percent, extend credit, and speed up ordering through better software.

These are not the same customer, and treating them as one brand rather than two related businesses is a marketing convenience, not an operating reality. One is a patient walking into a store, comparing price and trust against every other pharmacy on the street. The other is a pharmacy owner deciding whether to route purchasing through a platform run by a company that also owns competing retail outlets a few streets over. Sidley's public description of its pro bono engagement with Lifestores confirms the network spans "their own pharmacies, their affiliate pharmacies, and hospitals and clinics" under a platform called PharmIQ, which bundles retail point-of-sale software, the B2B group-purchasing layer, and business financing. The same document states Lifestores serves more than 100,000 patients a month, though that figure carries no date in the source and should be read as a claim from whenever that page was published, not a live count.

The mechanism, and the trust problem baked into it

The distribution logic has three moving parts. Lifestores aggregates independent pharmacy purchasing demand through OGApharmacy, which lets small operators access manufacturer pricing they could never negotiate alone — the same logic that makes buying groups work in any fragmented retail category. It attaches software to that transaction through PharmIQ, so a pharmacy that joins for the discount ends up running its point of sale, inventory and financing through Lifestores infrastructure, which is a much harder relationship to leave than a one-off wholesale order. And it uses direct sourcing from manufacturers as a trust signal — explicitly stated on the consumer site as a reason to believe the medicine is genuine, which matters enormously in a market where counterfeit and diverted pharmaceuticals are a real and recurring concern, as the UNDP's business-case framing of Nigerian pharmaceutical distribution makes explicit for the sector generally.

The trust problem is this: an independent pharmacist who joins OGApharmacy for cheaper stock is, by definition, also handing purchasing and sales data to a company that operates its own retail pharmacies in the same city. Nothing in the public record suggests Lifestores has misused that position. But the structural conflict is real and does not require bad intent to matter — it only requires the independent pharmacist to notice it, which sophisticated operators eventually do. A group-purchasing organisation that does not compete with its own members is a simpler trust proposition than one that does.

It is worth being precise about why this matters more in pharmacy than in most retail categories where buying groups are common. A hardware store that joins a co-op and later notices the co-op also runs competing stores can simply shop the price and move on; the switching cost is a few percentage points of margin. A pharmacy's relationship with its wholesaler carries regulatory and clinical weight that a hardware co-op does not — batch tracking, cold-chain handling, and the pharmacist's own licence are all entangled with who supplies the shelf. That raises the bar for what "neutral platform" has to mean before an independent operator will treat OGApharmacy as core infrastructure rather than a discount channel to be used opportunistically and hedged against with a second supplier relationship.

Where the economics get hard

The public funding history is instructive. CFAO Group's 2022 announcement records a $3 million pre-Series A led by Health54, CFAO's healthcare venture arm, with Aruwa Capital Management supporting. That announcement described plans for predictive ordering, advanced credit tools and patient-management pilots — a reasonably ambitious software roadmap for a $3 million round. As of this analysis, there is no publicly disclosed Series A or later round for Lifestores. Startup Intros' funding tracker lists the same $3 million round as the company's only disclosed raise, still current as of writing. That is a modest capital base for a company trying to run retail pharmacies, extend merchant credit to independent operators, and build software simultaneously.

Each of those three activities is capital-intensive on its own. Retail pharmacy requires inventory and property costs. Credit extension to independent pharmacies requires a balance sheet that can absorb defaults, and community pharmacy is not a low-default category in a market with currency volatility and thin margins. Software requires sustained product investment regardless of how many customers are using it. Running all three off a $3 million round, without a visible follow-on, suggests a company that has had to choose between depth and breadth more often than its public messaging admits.

The decision this suggests for a Nigerian operator

If you are deciding whether to build the operator-first, software-second model that Lifestores chose, the decision is not whether owning outlets teaches you the business — it clearly does, and the specificity of Lifestores' provider proposition (10 to 20 percent procurement savings, not a vague "save money" claim) reads like something learned by running a till, not by interviewing pharmacists. The decision is whether you are willing to accept that owning outlets makes your platform business harder to sell to the exact customers you need it to scale with. Lifestores chose depth of understanding over structural neutrality. That is a defensible choice for the first few years of a company, when learning the operating reality matters more than anything else. It becomes a liability at scale, when the retail arm starts competing for the same wallet the marketplace is trying to aggregate. The operator decision is whether to plan, from the start, for a point at which the retail chain and the marketplace either separate structurally or stop pretending not to compete.

What would change this read

The open question is whether Lifestores has resolved, or plans to resolve, the conflict between owning stores and selling neutral infrastructure to competing stores. Evidence that would settle it: a disclosed Series A or later round sized to fund credit extension without starving the software roadmap, a stated policy on how OGApharmacy pricing compares for independent members versus Lifestores' own outlets, or a structural separation of the retail and marketplace businesses. Absent any of those, the safer assumption is that Lifestores remains a well-run pharmacy chain that has built useful tools for its peers, rather than a platform business that happens to also run some stores — a smaller and more concentrated business than the "healthtech platform" framing suggests.

Sources consulted

• Lifestores Healthcare B2B site
• Lifestores Pharmacy consumer site
• Sidley Emerging Enterprises: Lifestores project description
• CFAO Group: Lifestores closes $3M pre-Series A, 2022
• Startup Intros: Lifestores Healthcare funding tracker
• UNDP SDG Investor Platform: Nigerian pharmaceutical distribution business case